Full-Time
Confirmed live in the last 24 hours
Advanced cardiac monitoring solutions provider
$94.1k - $138.1kAnnually
Senior, Expert
Cypress, CA, USA
The job is located in Orange County, CA, specifically in Cypress, CA.
You match the following iRhythm Technologies's candidate preferences
Employers are more likely to interview you if you match these preferences:
iRhythm Technologies specializes in cardiac monitoring solutions, particularly through its main product, the Zio Patch. This wearable device allows for up to 14 days of continuous heart rhythm tracking, enabling healthcare providers to detect irregular heart rhythms that shorter monitoring periods might miss. The Zio Patch is especially useful for patients who suspect heart issues, as it allows them to monitor their heart activity without frequent visits to the doctor, which is important in the current telehealth environment. iRhythm serves both patients and healthcare providers, selling the Zio Patch and offering data analysis services to interpret the collected heart data. This focus on extended monitoring and data analysis sets iRhythm apart from competitors in the healthcare and medical device market. The company's goal is to enhance patient outcomes and improve healthcare workflows through advanced cardiac monitoring.
Company Size
1,001-5,000
Company Stage
IPO
Total Funding
$102.8M
Headquarters
San Francisco, California
Founded
2006
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Holidays
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Mental Health Support
Hybrid Work Options
Pet Insurance
iRhythm Technologies announced that the company has signed an exclusive license agreement with BioIntelliSense, a continuous health monitoring and clinical intelligence company, to develop and commercialize certain patented technology assets within ambulatory cardiac monitoring, ACM.
iRhythm announces commercial launch of its Zio LTCM.
iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company has signed an exclusive license agreement with BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, to develop and commercialize certain patented technology assets within ambulatory cardiac monitoring (ACM).
Daiwa Securities Group Inc. makes new $1.93 million investment in iRhythm Technologies, Inc. (NASDAQ:IRTC).
SAN FRANCISCO - iRhythm Technologies, Inc. (NASDAQ:IRTC), a digital healthcare company, announced the commercial launch of its Zio monitor and Zio long-term continuous ambulatory ECG monitoring (LTCM) service in Austria, the Netherlands, Spain, and Switzerland.
iRhythm Technologies, Inc. (IRTC) has officially launched its Zio monitor and long-term continuous (LTCM) ECG monitoring service in Austria, the Netherlands, Spain and Switzerland.
Recently a securities fraud complaint was filed against iRhythm on behalf of investors who purchased shares of the company's stock between November 5, 2021 and May 30, 2023 (the "Class Period").
The letter accused iRhythm of violating Federal Food, Drug, and Cosmetic Act rules about labeling, medical device reporting, and quality systems.
Wilson, who will take over as CFO, joined iRhythm in 2019 and has been instrumental in guiding the company through its initial public offering.
iRhythmSAN FRANCISCO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 43rd Annual J.P. Morgan Healthcare Conference.Recent Operational Highlights and Financial OutlookAnticipate full year 2024 revenue slightly above high end of previously stated guidance range of $587.5 million provided in October 2024Record quarter of new account openings for both Zio monitor and Zio AT during the fourth quarter 2024 as well as strong volume contributions from large national accountsLaunched first four health care systems on Epic Aura during the fourth quarter 2024 with broad commercial roll out for Epic health systems across the U.S. beginning in 2025Initiated Zio monitor shipments for home enrollment patients during the fourth quarter 2024Five studies presented at the American Heart Association highlight Zio Monitor’s high patient satisfaction, engagement and compliance with the patient MyZio app and digital tools, health economic impact of early arrhythmia detection in type 2 diabetes and respiratory disease, and AI insights on sleep and activity patterns 1Expect revenue for the full year 2025 of approximately $675 million to $685 million“This past year was a period of significant growth and transformation for iRhythm,” said Quentin Blackford, iRhythm’s President and CEO. “In our core U.S
Dynamic Technology Lab Private Ltd invests $1.50 million in iRhythm Technologies, Inc. (NASDAQ:IRTC).